Description
Status BTA is a rapid test for the qualitative detection of bladder tumor associated antigen in human urine. It is indicated as an aid in monitoring bladder cancer patients in conjunction with cystoscopy, and it returns results in 5 minutes from a CLIA waived format.
- Five-Minute Results – The qualitative readout completes while the monitoring visit is still in progress.
- CLIA Waived Format – The waived urine test fits office and clinic monitoring workflows without laboratory complexity.
- Urine Specimen – A non-invasive urine sample drives the test, suiting repeat monitoring schedules.
Urine BTA Testing for Bladder Cancer Monitoring
Bladder cancer surveillance runs on schedules, and this test supports the monitoring side of that care. It qualitatively detects bladder tumor associated antigen in human urine as an aid in monitoring patients, used in conjunction with cystoscopy rather than in place of it. LifeSign lists the format as CLIA waived, with results in 5 minutes and superior sensitivity and specificity in the manufacturer's reporting. The urine specimen keeps collection non-invasive for patients on repeat visits. Each box holds 25 tests. Urology and oncology practices use it to add a rapid data point between cystoscopy appointments.
Features and Benefits
Monitoring Role
- Adjunct to Cystoscopy – The indication pairs the test with cystoscopy, adding a urine marker to the visual examination schedule.
- Five-Minute Turnaround – Results land during the appointment, so the monitoring conversation uses them the same day.
Practice Fit
- CLIA Waived – The waived category suits office-based monitoring programs and clinic laboratories.
- Repeat-Visit Friendly – A urine specimen and a five-minute read fit the cadence of surveillance schedules.
Product Specifications
Test Details
- Analyte: Bladder tumor associated antigen
- Specimen: Human urine
- Result Time: 5 minutes
- CLIA Category: Waived
Packaging
- Tests per Box: 25
- Packaging: Sold by the box, each
- Intended Use: Aid in monitoring bladder cancer patients, in conjunction with cystoscopy
Browse the full Immunoassay Kits range, or shop everything from LifeSign.
Why Choose the Status BTA Test
Monitoring programs need data points between cystoscopies, and a five-minute urine test supplies one without another procedure. The waived format keeps it practical for the offices that run surveillance schedules. For bladder cancer monitoring, that convenience is the difference.
- Same-Visit Answers – A five-minute result feeds the monitoring discussion while the patient is still in the office.
- Non-Invasive Collection – Urine sampling suits patients returning on long surveillance schedules.
- Designed for Monitoring – The indication is monitoring-focused, matching the test to its surveillance role alongside cystoscopy.
Frequently Asked Questions
What analyte does it detect?
It qualitatively detects bladder tumor associated antigen in human urine. The test aids in monitoring bladder cancer patients.
Does it replace cystoscopy?
No, the indication is use in conjunction with cystoscopy. The urine result adds a marker data point to the monitoring schedule.
How fast are results?
Results read in 5 minutes. The CLIA waived format suits office and clinic settings.
What specimen does it use?
The test uses human urine. Collection is non-invasive, which suits repeat monitoring visits.
What quantity comes in a box?
Each box holds 25 tests. Boxes are sold individually.
